{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T22:39:50Z","timestamp":1773268790539,"version":"3.50.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      The rise of drug-resistant tuberculosis poses a significant challenge in patient management. Epidemiological cut-off values define drug resistance in\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      . In our previous study, we reported deviations from the WHO-recommended epidemiological cut-off values and identified subtherapeutic concentrations of rifampicin in clinical\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      isolates. Building on these findings, the present study systematically evaluated the epidemiological cut-off values and pharmacodynamic profiles of newer and repurposed second-line anti-TB drugs - Bedaquiline, Delamanid, Moxifloxacin, Linezolid, Clofazimine, Levofloxacin, and Pretomanid against the first-line drug-sensitive and isolates that are resistant to Rifampicin and Isoniazid from tuberculosis patients in and around Chennai.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The Broth microdilution-based Microscopic Observation Drug Susceptibility assay was employed to determine the minimum inhibitory concentration of the drugs against well-characterized wild-type and drug-resistant clinical\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      clinical isolates. The resulting MIC profiles were subsequently analyzed to delineate pharmacodynamic relationships underlying therapeutic efficacy and resistance development.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and discussion<\/jats:title>\n                    <jats:p>\n                      Deviations from the World Health Organization\u2013recommended epidemiological cut-off values were observed, with lower thresholds for delamanid and levofloxacin and higher concentrations for clofazimine and bedaquiline. These shifts indicate region-specific susceptibility patterns in\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      that have direct implications for the effective treatment of multidrug-resistant tuberculosis. Inaccurate cut-off values may lead to misclassification of resistance, inappropriate regimen selection, and exposure to suboptimal drug concentrations, thereby compromising treatment efficacy and amplifying the risk of acquired resistance. Concordantly, pharmacodynamic analyses revealed sub-therapeutic exposure ranges for several newer and repurposed anti-TB drugs, underscoring the potential for treatment failure even in strains classified as susceptible. Collectively, these findings highlight the urgent need for regionally calibrated epidemiological cut-off values to optimize drug dosing, improve MDR-TB treatment outcomes, and strengthen resistance surveillance frameworks.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1739149","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:52:20Z","timestamp":1773211940000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Wild-type MIC distribution and evaluation of epidemiological cut-offs of second-line TB-drugs in susceptible and MDR-TB clinical isolates from Chennai, India"],"prefix":"10.3389","volume":"17","author":[{"given":"Azger","family":"Dusthackeer","sequence":"first","affiliation":[{"name":"Department of Bacteriology, ICMR-National Institute for Research in Tuberculosis","place":["Chennai, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahizhaveni","family":"Balasubramanian","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, ICMR-National Institute for Research in Tuberculosis","place":["Chennai, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam Ebenezer","family":"Rajadas","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, ICMR-National Institute for Research in Tuberculosis","place":["Chennai, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy Rosaline","family":"Nirmal","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, ICMR-National Institute for Research in Tuberculosis","place":["Chennai, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padmasini","family":"Elango","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, ICMR-National Institute for Research in Tuberculosis","place":["Chennai, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kannan","family":"Thiruvengadam","sequence":"additional","affiliation":[{"name":"Department of Statistics, ICMR-National Institute for Research in Tuberculosis","place":["Chennai, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shainaba A.","family":"Saadhali","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, ICMR-National Institute for Research in Tuberculosis","place":["Chennai, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivakumar","family":"Shanmugam","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, ICMR-National Institute for Research in Tuberculosis","place":["Chennai, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1093\/jac\/dkaa310","article-title":"Clofazimine pharmacokinetics in patients with TB: Dosing implications.","volume":"75","author":"Abdelwahab","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1128\/AAC.00276-15","article-title":"Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry.","volume":"59","author":"Alffenaar","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"612675","DOI":"10.3389\/fmicb.2021.612675","article-title":"Evolution of drug-resistant Mycobacterium tuberculosis strains and their adaptation to the human lung environment.","volume":"12","author":"Allu\u00e9-Guardia","year":"2021","journal-title":"Front. Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1128\/AAC.00232-11","article-title":"Wild-Type MIC distributions must be considered to set clinically meaningful susceptibility testing breakpoints for all bacterial pathogens, including Mycobacterium tuberculosis.","volume":"55","author":"\u00c4ngeby","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"955050","DOI":"10.3389\/fphar.2022.955050","article-title":"Linezolid resistance in multidrug-resistant Mycobacterium tuberculosis: A systematic review and meta-analysis.","volume":"13","author":"Azimi","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e01304","DOI":"10.1128\/JCM.01304-20","article-title":"Characterization of genomic variants associated with resistance to bedaquiline and delamanid in Na\u00efve Mycobacterium tuberculosis clinical strains.","volume":"58","author":"Battaglia","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/FTD.0000000000001164","article-title":"Effect of bedaquiline and delamanid pharmacokinetics on sputum culture conversion and adverse events in drug-resistant tuberculosis.","volume":"46","author":"Bhatnagar","year":"2024","journal-title":"Ther. Drug Monit."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/cid\/ciab335","article-title":"Effectiveness and cardiac safety of bedaquiline-based therapy for drug-resistant tuberculosis: A prospective cohort study.","volume":"73","author":"Brust","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1038\/s41467-022-30635-7","article-title":"Seeking patterns of antibiotic resistance in ATLAS, an open, raw MIC database with patient metadata.","volume":"13","author":"Catal\u00e1n","year":"2022","journal-title":"Nat. Commun."},{"key":"B10","volume-title":"National Guidelines for Management of Drug Resistant TB: National TB Elimination Programme.","year":"2024"},{"key":"B11","volume-title":"Tuberculosis (TB) Clinical Guidelines.","year":"2024"},{"key":"B12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/jac\/dkw426","article-title":"Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.","volume":"72","author":"Cholo","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJMoa1715849","article-title":"Bacterial factors that predict relapse after tuberculosis therapy.","volume":"379","author":"Colangeli","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2200239","DOI":"10.1183\/13993003.00239-2022","article-title":"Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis.","volume":"60","year":"2022","journal-title":"Eur. Respir. J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2300426","DOI":"10.1183\/13993003.00426-2023","article-title":"Reply: Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis.","volume":"61","year":"2023","journal-title":"Eur. Respir. J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S293","DOI":"10.1093\/cid\/ciy611","article-title":"Levofloxacin pharmacokinetics\/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant Tuberculosis.","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1164\/rccm.200901-0146OC","article-title":"Fluoroquinolone resistance in Mycobacterium tuberculosis: The effect of duration and timing of fluoroquinolone exposure.","volume":"180","author":"Devasia","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-024-00504-2","article-title":"Multidrug-resistant tuberculosis.","volume":"10","author":"Dheda","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3389\/fmicb.2020.01182","article-title":"Wild-Type MIC distribution for re-evaluating the critical concentration of Anti-TB drugs and pharmacodynamics among Tuberculosis patients from South India.","volume":"11","author":"Dusthackeer","year":"2020","journal-title":"Front. Microbiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e00141-20","DOI":"10.1128\/CMR.00141-20","article-title":"Mechanisms of drug-induced tolerance in Mycobacterium tuberculosis.","volume":"34","author":"Goossens","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1128\/AAC.01474-09","article-title":"New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic\/pharmacodynamic science and population pharmacokinetic variability.","volume":"54","author":"Gumbo","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1086\/424849","article-title":"Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.","volume":"190","author":"Gumbo","year":"2004","journal-title":"J. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.5588\/ijtld.16.0048","article-title":"Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.","volume":"20","author":"Hemanth Kumar","year":"2016","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1027394","DOI":"10.3389\/fcimb.2022.1027394","article-title":"The evolving biology of Mycobacterium tuberculosis drug resistance.","volume":"12","author":"Jones","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1128\/JCM.00240-10","article-title":"Wild-Type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections.","volume":"48","author":"Jur\u00e9en","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0291920","DOI":"10.1128\/JCM.02919-20","article-title":"Bedaquiline drug resistance emergence assessment in Multidrug-Resistant Tuberculosis (MDR-TB): A 5-Year prospective in vitro surveillance study of bedaquiline and other second-line drug susceptibility testing in MDR-TB isolates.","volume":"60","author":"Kaniga","year":"2022","journal-title":"J. Clin. Microbiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.4155\/fmc-2018-0378","article-title":"Novel 1, 3, 4-oxadiazoles as antitubercular agents with limited activity against drug-resistant tuberculosis.","volume":"11","author":"Makane","year":"2019","journal-title":"Future Med. Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e01207-20","DOI":"10.1128\/AAC.01207-20","article-title":"Cumulative fraction of response for once- and twice-daily delamanid in patients with pulmonary multidrug-resistant Tuberculosis.","volume":"65","author":"Mallikaarjun","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jgar.2017.08.014","article-title":"Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.","volume":"12","author":"Mamatha","year":"2018","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2003300","DOI":"10.1183\/13993003.03300-2020","article-title":"World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.","volume":"57","author":"Mirzayev","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1093\/jac\/dky232","article-title":"Variation of MIC measurements: The contribution of strain and laboratory variability to measurement precision.","volume":"73","author":"Mouton","year":"2018","journal-title":"J. Antimicrob. Chemotherapy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/S1473-3099(21)00811-2","article-title":"Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: A retrospective cohort study.","volume":"22","author":"Ndjeka","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"954074","DOI":"10.3389\/fcimb.2022.954074","article-title":"Evolution of Mycobacterium tuberculosis drug resistance in the genomic era.","volume":"12","author":"Nimmo","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0301060","DOI":"10.1371\/journal.pone.0301060","article-title":"Progress and challenges in achieving tuberculosis elimination in India by 2025: A systematic review and meta-analysis.","volume":"19","author":"Padhi","year":"2024","journal-title":"PLoS One"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e900","DOI":"10.1128\/AAC.00900-17","article-title":"In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant Tuberculosis in Beijing, China.","volume":"61","author":"Pang","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1128\/AAC.00354-15","article-title":"Pharmacokinetics of second-line antituberculosis drugs after multiple administrations in healthy volunteers.","volume":"59","author":"Park","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1128\/AAC.00177-10","article-title":"Therapeutic drug monitoring of linezolid: A retrospective monocentric analysis.","volume":"54","author":"Pea","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/jac\/dkp262","article-title":"Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.","volume":"64","author":"Schon","year":"2009","journal-title":"J. Antimicrob. Chemotherapy"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e0159421","DOI":"10.1128\/spectrum.01594-21","article-title":"Mycobacterium tuberculosis lineages associated with mutations and drug resistance in isolates from India.","volume":"10","author":"Shanmugam","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"B40","doi-asserted-by":"publisher","first-page":"100599","DOI":"10.1016\/j.ijregi.2025.100599","article-title":"Lessons and updates from India\u2019s National Tuberculosis Elimination Program \u2013 bold decisions and innovative ways of fast-tracking progress toward ending tuberculosis.","volume":"14","author":"Singh","year":"2025","journal-title":"IJID Regions"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e00751-17","DOI":"10.1128\/AAC.00751-17","article-title":"Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for Tuberculosis.","volume":"61","author":"Srivastava","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1100488","DOI":"10.3389\/fphar.2023.1100488","article-title":"Clofazimine for the treatment of Tuberculosis.","volume":"14","author":"Stadler","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1128\/AAC.03014-15","article-title":"MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration.","volume":"60","author":"Stinson","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"21746","DOI":"10.1038\/s41598-025-04038-9","article-title":"The identification Mycobacterium tuberculosis genes that modulate long term survival in the presence of rifampicin and streptomycin.","volume":"15","author":"Toloza","year":"2025","journal-title":"Sci. Rep."},{"key":"B45","unstructured":"Uma Devi\n              K. R.\n            \n          \n          Indian Catalouge of Mycobacterium tuberculosis mutations and their Association with Drug Resistance - 2022\n          \n          2022"},{"key":"B46","doi-asserted-by":"publisher","first-page":"567","DOI":"10.5588\/ijtld.22.0632","article-title":"Linezolid resistance in patients with drug-resistant TB.","volume":"27","author":"Vengurlekar","year":"2023","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e01439-20","DOI":"10.1128\/AAC.01439-20","article-title":"Most-Probable-Number-Based minimum duration of killing assay for determining the spectrum of rifampicin susceptibility in clinical Mycobacterium Tuberculosis isolates.","volume":"65","author":"Vijay","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2100361","DOI":"10.1183\/13993003.00361-2021","article-title":"New definitions of pre-extensively and extensively drug-resistant tuberculosis: Update from the World Health Organization.","volume":"57","author":"Viney","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B49","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1186\/s12879-025-11356-w","article-title":"Whole-genome sequencing for analyzing the transmission characteristics of drug-resistant Mycobacterium tuberculosis in Ganzhou, China.","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Infect. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1128\/AAC.05894-11","article-title":"Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.","volume":"56","author":"Werngren","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B51","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1128\/AAC.00798-13","article-title":"Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects.","volume":"57","author":"Winter","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B52","volume-title":"Global Tuberculosis Report.","year":"2025"},{"key":"B53","volume-title":"Catalogue of Mutations in Mycobacterium tuberculosis Complex and their Association with Drug Resistance","year":"2023"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e0270003","DOI":"10.1371\/journal.pone.0270003","article-title":"Risk factors for multidrug-resistant tuberculosis: A worldwide systematic review and meta-analysis.","volume":"17","author":"Xi","year":"2022","journal-title":"PLoS One"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e3520","DOI":"10.1093\/cid\/ciaa1569","article-title":"Drug exposure and minimum inhibitory concentration predict pulmonary Tuberculosis treatment response.","volume":"73","author":"Zheng","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2101925","DOI":"10.1183\/13993003.01925-2021","article-title":"Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: A multicentre prospective cohort study in China.","volume":"59","author":"Zheng","year":"2022","journal-title":"Eur. Respir. J."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1739149\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:52:23Z","timestamp":1773211943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1739149\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":56,"alternative-id":["10.3389\/fmicb.2026.1739149"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1739149","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"article-number":"1739149"}}